NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

Researchers conducted the REDEFINE 1 and REDEFINE 2 clinical trials to assess the effect of CagriSema on weight loss in obesity with or without type 2 diabetes.

A NEW Phase 3 trial has shown that a combination therapy of cagrilintide and semaglutide (CagriSema) can lead to substantial ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema fuelled ...

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Novo Nordisk A/S (NYSE:NVO) is ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster ...

The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss-up to 24% with ...

July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...